UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 14, 2025 (Commission File Number) (I.R.S. Employer Identification No.) 978-349-3200 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to sim ...

Fourth quarter 2024 total revenue expected to be a record at approximately $8.2 million, representing growth of approximately 30% compared to the prior-year period. Fourth quarter 2024 recurring revenue expected to be approximately $4.2 million, representing growth of approximately 27% compared to the prior-year period. Full year 2024 total revenue expected to be approximately $28.1 million, representing growth of approximately 25% compared to the prior year. Full year 2024 recurring revenue expected to be ...

LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference. The Company is scheduled to present on Thursday, January 16, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Ti ...

LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference. Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 30-minute question-and-answer ses ...

Table of Contents ________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ ...

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q3 2024 Results Conference Call November 1, 2024 9:00 AM ET Company Participants Michael Beaulieu - CFA, VP, IR & Corporate Communications Robert Spignesi - President & CEO Sean Wirtjes - CFO Conference Call Participants Brendan Smith - TD Cowen Dan Arias - Stifel Operator Thank you for standing by. My name is Novi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Rapid Micro Biosystems Third Quarter 2024 Earnings ...

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.26 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.29, delivering a surprise of -3.57%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Rapid Micro Biosystems, which ...

Exhibit 99.1 Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results • Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023 • Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 ◦ Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout • Ach ...

Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company miles ...

LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. In conjunction with the release, the Company’s management team will host a webcast conference call beginning at ...